A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT03422328

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03422328
  • EudraCT 2017-003934-10
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belarus, Belgium, France, Poland, Russia, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03422328. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2023-12-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
Acronym
UMBRELLA
Condition
Pulmonary Arterial Hypertension
Condition
Chronic Thromboembolic Pulmonary Hypertension
Intervention (Drug)
macitentan
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct03422328
Content hash
68eed971df7d9285113e044763e37270fea4d7f6b9986c421b93b1ad3b607755